Lead Product(s): ETD002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $96.8 milion
Deal Type: Acquisition October 07, 2020
Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.